MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gen ...

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST ...

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST ...

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (Phase 1/2 ArMaDa clinical trial), and OCU410ST ...

Ocugen公司数据发布 - Ocugen公司有两项即将发布的数据结果，分别涉及OCU-410和OCU-410ST的使用，这可能会推动股东价值上升[1] - OCU-410和OCU-410ST的数据结果作为近期催化剂可能会提高股东价值[4] - Ocugen公司计划在2024年发布两项数据结果，一项是关于治疗地理性萎缩症（GA）患者的OCU-410，另一项是关于治疗斯塔加特病（Stargardt Disease）患者的OCU-410ST[3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________ FORM 10-K ___________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36751 _______________________ ...

Ocugen公司业务介绍 - Ocugen公司是一家专注于发现、开发和商业化新型基因和细胞疗法、生物制剂和疫苗的生物技术公司，致力于改善全球患者的健康并为他们带来希望[4] Shankar Musunuri博士参加Emerging Growth Virtual Healthcare Equity Conference - Ocugen公司宣布董事长、首席执行官和联合创始人Shankar Musunuri博士将参加由Noble Capital Markets举办的Emerging Growth Virtual Healthcare Equity Conference的炉边聊天[1] Ocugen公司临床发展进展 - Musunuri博士将展示公司最近的业务和临床发展进展，包括FDA批准启动OCU400第三期临床试验，这是一种用于治疗视网膜色素变性症（RP）患者的修饰基因疗法[2]

MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the pivotal OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and provi ...

Ocugen公司新闻 - Ocugen公司宣布其候选药物OCU410的早期至中期研究的数据和安全监控委员会（DSMB）已批准在治疗患有地理性萎缩（GA）的患者中使用OCU410的中剂量进行剂量递增阶段的治疗，这标志着确定OCU410最佳剂量方案的关键一步[1] - 公司股价在4月5日最后一个交易日上涨了21.2%，并在公告后的盘后交易中继续上涨了2.7%[2] - OCU410利用AAV传递平台进行视网膜传递RORA基因，该基因在治疗GA中起重要作用，公司认为OCU410有潜力成为首个一次性修饰基因治疗GA的候选药物，股价年初以来已飙升218.3%[4]

Ocugen (NASDAQ:OCGN) stock rose about 10% over the weekend. This comes after the company won U.S. Food and Drug Administration (FDA) clearance to advance its rare eye disease treatment to a Phase 3 trial. OCU400 is a gene therapy being developed for retinitis pigmentosa (RP). RP causes the retina at the back of the eye to break down over time, eventually resulting in blindness. Shares of OCGN are up more than 7% as of this writing, at around $1.90 per share and a market capitalization of roughly $485 millio ...